Leerink affirms Heron Therapeutics (Nasdaq: HRTX) at Outperform with a price target of $33 following FDA approval of Sustol for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

FDA's Letter to Heron Therapeutics (HRTX) Over Sustol ApprovalAugust 10, 2016 12:50 PM Form 8-K HERON THERAPEUTICS, INC. For: Aug 09August 10, 2016 8:43 AM Heron Therapeutics (HRTX) Reports FDA Approval of SUSTOLAugust 10, 2016 8:33 AM Heron Therapeutics Announces U.S. FDA Approval of SUSTOL® (granisetron) Extended-Release Injection for the Prevention of Chemotherapy-Induced Nausea and VomitingAugust 10, 2016 8:30 AM Heron Therapeutics (HRTX) Halted, News PendingAugust 10, 2016 8:25 AM Form 10-Q HERON THERAPEUTICS, INC. For: Jun 30August 8, 2016 4:51 PM Form 8-K HERON THERAPEUTICS, INC. For: Aug 08August 8, 2016 4:11 PM